|
Daily Medical Update
Opioid Use Disorder & Buprenorphine in Primary Care
Wednesday, March 11, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Cochrane Database Syst Rev (2025) - Systematic Review/Meta-analysis
Key Findings
- Across 7 randomized trials (n=1,952), treatment retention in primary care was similar to specialty care (RR 1.15, 95% CI 0.98-1.34).
- Abstinence from non-prescribed opioids favored primary care models in pooled analysis (RR 1.59, 95% CI 1.03-2.46), though certainty was low.
📋 Practice Implication: In stable lower-risk patients, primary care can be used as a frontline OAT setting to widen access without waiting for specialty placement.
|
JAMA Network Open (2025) - Secondary Analysis of RCTs
Key Findings
- Adding behavioral therapy to buprenorphine plus medical management did not improve opioid-free weeks (B=0.28; 95% CI -0.33 to 0.89; P=.37).
- Adjunct behavioral therapy also did not improve buprenorphine retention over 12 weeks (B=0.00; 95% CI -0.43 to 0.43; P=.98).
📋 Practice Implication: When capacity is tight, prioritize same-day buprenorphine initiation and reliable follow-up medical management rather than delaying starts for additional therapy availability.
|
JAMA Network Open (2025) - Cluster RCT Secondary Analysis
Key Findings
- Hospital addiction consult implementation lowered post-discharge emergency department use (IRR 0.79, 95% CI 0.72-0.88; P<.001).
- No significant differences were detected in rehospitalization (IRR 0.99) or all-cause mortality (HR 1.14, 95% CI 0.98-1.92).
📋 Practice Implication: After OUD hospitalization, schedule proactive primary-care transition visits and outreach because consult effects appear strongest on acute utilization, not death risk reduction.
|
Implementation Science (2025) - Cluster RCT
Key Findings
- Enhanced implementation support increased contingency-management delivery exposure (OR 3.21) and high-fidelity competence (OR 4.07) versus standard support.
- Patients in enhanced-support sites had higher odds of opioid abstinence over time (OR 2.04).
📋 Practice Implication: If adding contingency management to MOUD workflows, pair staff facilitation and incentive infrastructure with training to improve measurable abstinence outcomes.
|
Drug and Alcohol Dependence (2025) - Randomized Controlled Trial
Key Findings
- In inpatient withdrawal treatment, completion rates were equivalent with methadone and buprenorphine (82.5% vs 82.0%; p=0.95).
- Methadone produced greater withdrawal-score improvement (COWS/SOWS, p=0.01), while side-effect rates were comparable between groups.
📋 Practice Implication: For withdrawal management, select methadone or buprenorphine based on which option best preserves next-step maintenance continuity in your local outpatient network.
|
|
Recent evidence supports expanding office-based treatment for opioid use disorder in primary care while focusing on pragmatic delivery choices that improve access and continuity. Across randomized and meta-analytic data, buprenorphine with structured medical management remains a strong core intervention, and primary care opioid agonist therapy can achieve outcomes comparable to specialty settings in appropriate patients. Implementation quality and post-discharge linkage planning appear to drive practical gains more than simply adding extra counseling layers.
|
|